Recbio Reports Shingles Vaccine Milestone and Delay in HPV FilingTip Ranks·Jul 23 at 05:40 AM02179-0.60%
Jiangsu Recbio says NMPA accepts filing for REC610 shingles vaccine approvalPUBT·Jul 23 at 05:25 AM02179-0.60%
Beijing Ubox Online files HKEX next-day disclosure return on share repurchase for cancellationPUBT·Jul 21 at 05:00 AM02179-0.60%02429+3.70%
RECBIO H shares full circulation has been filed with the China Securities Regulatory Commission, involving a conversion of 24% equity in H sharesAASTOCKS·Feb 1 at 08:57 PM02179-0.60%
Recbio Gains CSRC Green Light for Full Circulation of 142 Million Domestic Shares as H SharesTip Ranks·Jan 30 at 09:09 AM02179-0.60%
RECBIO has obtained approval for the CHO cell vaccine expansionAASTOCKS·Nov 16, 2025 at 04:42 AM02179-0.60%
"Performance" RECBIO's mid-term loss expands to 341 million RMBAASTOCKS·Aug 31, 2025 at 02:31 AM02179-0.60%
RECBIO-B released its interim results, with a loss attributable to shareholders of 341 million yuan, an increase of 36.7% year-on-yearZhitong·Aug 29, 2025 at 06:23 AM02179-0.60%
RECBIO-B's targeted issuance of domestic shares has been approved by the China Securities Regulatory CommissionZhitong·Jul 23, 2025 at 06:25 AM02179-0.60%
RECBIO-B has reached a product authorization cooperation with India's Biological E for the restructured nine-valent HPV vaccine REC603Zhitong·Jun 30, 2025 at 04:40 AM02179-0.60%
RECBIO-B: Chen Gang appointed as observer of the second board of directorsZhitong·Jun 20, 2025 at 05:01 AM02179-0.60%
